For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 75,365 | 72,992* | 68,989 | 62,203 |
| General and administrative | 28,242 | 21,966* | 14,366 | 13,379 |
| Total operating expenses | 103,607 | 94,957 | 83,355 | 75,582 |
| Loss from operations | -103,607 | -94,957* | -83,355 | -75,582 |
| Change in fair value of cvr liability | - | 0* | - | - |
| Interest income | 7,608 | -87* | 3,887 | 2,373 |
| Interest expense | 1,213 | 403* | 1,459 | 314 |
| Loss on debt extinguishment | - | -1,795* | - | - |
| Other income (expense), net | -140 | -6* | -3 | -6 |
| Total other income, net | 6,255 | -2,291* | 2,425 | 2,053 |
| Net loss | -97,352 | -97,248* | -80,930 | -73,529 |
| Net unrealized gains (losses) on marketable securities | -770 | -158 | 195 | -151 |
| Total other comprehensive income (loss) | -770 | -158* | 195 | -151 |
| Comprehensive loss | -98,122 | -97,406 | -80,735 | -73,680 |
| Basic EPS | -132.58 | -1,440.925 | -125.45 | -0.53 |
| Diluted EPS | -132.58 | -1,440.925 | -125.45 | -0.53 |
| Basic Average Shares | 67,414 | 67,600* | 67,414 | 114,466,080 |
| Diluted Average Shares | 67,414 | 67,600* | 67,414 | 114,466,080 |
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)